Renal handling of fleroxacin in rabbits, dogs, and humans.

Antimicrobial Agents and Chemotherapy
K ShibaT Ooie

Abstract

The renal handling of fleroxacin was studied by renal clearance and stop-flow techniques in rabbits and dogs and by analyzing the pharmacokinetics with and without probenecid in humans. In rabbits the excretion ratios (fleroxacin intrinsic renal clearance/glomerular filtration rate) were greater than unity (2.01) without probenecid and were decreased to a value below unity (0.680) with probenecid. In dogs, on the other hand, the excretion ratios were less than unity (0.608 and 0.456) both without and with probenecid, and so were not affected by probenecid. This fact suggested that fleroxacin was excreted into urine by both glomerular filtration and renal tubular secretion in rabbits, but only by glomerular filtration in dogs, accompanied by partial renal tubular reabsorption in both species; these mechanisms were also supported by stop-flow experiments. In humans probenecid treatment induced increases in the elimination half-life and area under the serum concentration-time curve and decreases in apparent serum clearance, renal clearance, and urinary recovery of fleroxacin. The excretion ratio without probenecid was 1.13, which was significantly decreased to 0.750 with probenecid. These results indicated that both renal tubular ...Continue Reading

References

Mar 1, 1979·Antimicrobial Agents and Chemotherapy·N RodriguezP G Welling
Oct 1, 1978·Journal of Clinical Pharmacology·K S IsraelJ D Wolney
Jun 1, 1986·Antimicrobial Agents and Chemotherapy·K HiraiT Irikura
Apr 1, 1986·Antimicrobial Agents and Chemotherapy·N X ChinH C Neu
Aug 1, 1986·Antimicrobial Agents and Chemotherapy·H KusajimaT Irikura
Feb 1, 1987·Antimicrobial Agents and Chemotherapy·R WiseD J Griggs
Dec 1, 1987·Antimicrobial Agents and Chemotherapy·E WeidekammP W Lücker
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·M NakashimaH Uchida
Jan 29, 1988·The Medical Letter on Drugs and Therapeutics
Dec 1, 1984·Journal of Pharmaceutical Sciences·M KoikeK Sugeno
Mar 1, 1981·Clinical Pharmacokinetics·R F CunninghamP G Dayton
Mar 1, 1982·Antimicrobial Agents and Chemotherapy·R H BarbhaiyaP G Welling

❮ Previous
Next ❯

Citations

Apr 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J S Wolfson, D C Hooper
Apr 26, 2000·Biochimica Et Biophysica Acta·P BielyJ Visser
Oct 1, 1994·Journal of Veterinary Pharmacology and Therapeutics·A R AbadíaM A Bregante
Oct 1, 1995·Zentralblatt für Veterinärmedizin. Reihe A·A R AbadiaM A Bregante
Jul 1, 2009·Antimicrobial Agents and Chemotherapy·Cornelia B LandersdorferFritz Sörgel
Feb 1, 1992·Antimicrobial Agents and Chemotherapy·G R GrannemanA G Pernet
Dec 1, 1995·Antimicrobial Agents and Chemotherapy·M NakashimaH Uchida
Mar 23, 2012·Expert Opinion on Drug Metabolism & Toxicology·Aditi MulgaonkarDouglas H Sweet
Apr 1, 1992·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·O OkazakiH Tachizawa
Mar 18, 2010·British Journal of Clinical Pharmacology·Cornelia B LandersdorferFritz Sörgel
Aug 9, 2017·Antimicrobial Agents and Chemotherapy·Max TaubertUwe Fuhr
Feb 18, 2017·Clinical Pharmacokinetics·Anton IvanyukThierry Buclin
Apr 4, 1998·Antimicrobial Agents and Chemotherapy·E F Foote, C E Halstenson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.